COLLEGIUM PHARMACEUTICAL, INC: FULLER & THALER ASSET MANAGEMENT, INC. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Fuller & Thaler Asset Management amended its Schedule 13G stake filing for Collegium Pharmaceutical, Inc., disclosing its updated passive position in the specialty pharma company to the SEC under accession number 0001420506-26-002805. The filing reflects the asset manager's current holdings in Collegium, which markets abuse-deterrent pain medications including Xtampza ER and Belbuca. Schedule 13G amendments are typically triggered when a passive investor's ownership crosses or adjusts past the 5% reporting threshold, making the disclosure a signal of institutional conviction in the name. Collegium shares and the company's ongoing revenue mix shift toward its pain portfolio will be in focus as investors digest the updated ownership data.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Collegium Pharmaceutical, Inc., Fuller & Thaler Asset Management, Inc.